Downregulation of PD‐L1 and HLA‐I in non‐small cell lung cancer with ALK fusion

BACKGROUND: Early clinical trials indicate that patients with anaplastic lymphoma kinase (ALK)‐driven non‐small cell lung cancer (NSCLC) have a lower response rate to programmed cell death protein 1 (PD‐1) antibody therapy. However, the specific mechanism underlying this remains unclear. To further...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Di, Guo, Jingjing, Yu, Wenwen, Zhang, Jiali, Ren, Xiubao, Han, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013653/
https://www.ncbi.nlm.nih.gov/pubmed/35253386
http://dx.doi.org/10.1111/1759-7714.14372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013653/
https://www.ncbi.nlm.nih.gov/pubmed/35253386
http://dx.doi.org/10.1111/1759-7714.14372

Ejemplares similares